Ramelteon

Category: sleep

Aliases: Rozerem

Pharmacological Mechanism

Selective MT1 + MT2 melatonin-receptor agonist with ~16× greater MT1 affinity than melatonin. No GABAergic activity → no dependence potential, no scheduling. Modest efficacy on sleep-onset latency (~10 min improvement). CYP1A2 substrate — fluvoxamine contraindicated (>200× AUC rise).

Half-Life (t½)

PO: 1.5h

Dosing Guidelines

• PO: Typical 8mg (Range: 8 - 8 mg)

Target Organ Systems

• endocrine
• digestive